Skip to main content

Williams Frank J's Form 4 filing

Evolent Health, Inc. (EVH) · filed Nov 3, 2022

Accession no.
0001628908-22-000143
Filed
Nov 3, 2022
Trade date
Nov 1, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.23M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Williams Frank JCIK 0001204938Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 1, 2022Class A Common StockMOption exerciseAcquired+110,000$3.84+$422,400736,479Direct
Nov 1, 2022Class A Common StockSSaleDisposed−38,112$28.88F4−$1,100,674.56698,367Direct
Nov 1, 2022Class A Common StockSSaleDisposed−57,438$29.36F5−$1,686,379.68640,929Direct
Nov 1, 2022Class A Common StockSSaleDisposed−13,773$30.26F6−$416,770.98627,156Direct
Nov 1, 2022Class A Common StockSSaleDisposed−677$31.81−$21,535.37626,479Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 1, 2022Class A Common StockMOption exerciseDisposed−110,000$0.00$0339,060Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.56 to $29.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.008 to $30.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.101 to $30.780, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)